Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q3 FY22 results · Oct–Dec 2021
Ajanta Pharma reported revenue from operations of ₹837.91 crore (up 11.9% from Q3 FY21) and net profit of ₹191.78 crore (up 8.6% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 837.91 | 748.74 | +11.9% | 884.80 | −5.3% |
| Other income | 24.03 | 5.48 | +338.5% | 29.54 | −18.7% |
| Total income | 861.94 | 754.22 | +14.3% | 914.34 | −5.7% |
| Profit before tax | 230.94 | 215.47 | +7.2% | 260.42 | −11.3% |
| Net profit for the period | 191.78 | 176.63 | +8.6% | 195.94 | −2.1% |
| EPS, basic (₹) | 22.16 | 20.41 | +8.6% | 22.64 | −2.1% |
| Net margin (%) | 22.9 | 23.6 | 22.1 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 808.58 | 733.16 | +10.3% | 823.71 | −1.8% |
| Other income | 27.90 | 2.90 | +862.1% | 52.41 | −46.8% |
| Total income | 836.48 | 736.06 | +13.6% | 876.12 | −4.5% |
| Profit before tax | 234.36 | 218.34 | +7.3% | 254.79 | −8.0% |
| Net profit for the period | 194.71 | 179.95 | +8.2% | 196.85 | −1.1% |
| EPS, basic (₹) | 22.50 | 20.80 | +8.2% | 22.75 | −1.1% |
| Net margin (%) | 24.1 | 24.5 | 23.9 |
Consolidated
- Filed with BSE
- 31 Jan 2022, 18:18 IST
- Board meeting
- 31 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jan 2022, 18:18 IST
- Board meeting
- 31 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE